Gt Biopharma, INC. (GTBP) — 10-Q Filings

10-Q Filings (6)

• GT Biopharma Narrows Losses, Equity Turns Positive Amid Cash Burn — Nov 14, 2025 Risk: high
  GT Biopharma, Inc. reported a net loss of $5.3 million for the nine months ended September 30, 2025, a significant improvement from the $9.387 million net loss
• GT Biopharma Narrows Losses, Raises Capital Amid Going Concern Doubts — Aug 14, 2025 Risk: high
  GT Biopharma, Inc. reported a net loss of $2.2 million for the six months ended June 30, 2025, a significant improvement from the $5.98 million net loss in the
• GT Biopharma Files Q1 2025 10-Q — May 15, 2025 Risk: low
  GT Biopharma, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS I
• GT Biopharma Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  GT Biopharma, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter and the first nine mont
• 10-Q Filing — Aug 14, 2024
• GT Biopharma, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk: low
  GT Biopharma, Inc. (GTBP) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. GT Biopharma, Inc. filed a 10-Q report for the period ending March 31, 2

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX